ASH 2014 | ASH 2014: Novel treatments for mantle cell lymphoma
Jia Ruan
Dr Jia Ruan (Weill Cornell Medical College, New York, NY) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses novel combination therapies that are currently being investigated in the clinic to address the unmet need in mantle cell lymphoma treatment. These therapeutic agents include bortezomib, lenalidomide, ibrutinib and rituximab.
Related videos
3:05
Allo-SCT upfront for MCL: feasible for a small subgroup?
Simon Rule
2:15
Defining the group of MCL patients who do well without treatment
Simon Rule
2:01
Ublituximab, umbralisib and ibrutinib in CLL and NHL
Loretta Nastoupil
1:39
Venetoclax monotherapy in MCL: longer-term results
Matthew Davids
2:40
Successful use of zanubrutinib for R/R MCL in China
Yuqin Song
